Draganfly Inc. Opens the Market at the CSE Media Centre

The CSE welcomed Draganfly Inc. (CSE:DFLY) to open the market on November 5th, 2019 at the CSE Media Centre.

Draganfly Inc. is an award-winning, industry-leading manufacturer, contract engineering, and product development company within the UAV space, serving the public safety, agriculture, industrial inspections, and mapping and surveying markets. The company is driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives. Draganfly is positioning itself as an integrated solutions provider to the UAV industry, and celebrated their recent listing on the CSE.

“Today for us at the Draganfly team to open up DFLY on the Canadian Securities Exchange, it’s humbling, quite frankly. This is an exchange that’s built for entrepreneurs, and we’re a company of entrepreneurs. This company has been around for 20-plus years, we had lots of options and opportunities of where we wanted to list, and this particular exchange, at this time, for this project, it was absolutely the right place to be,” remarked Chairman Cameron Chell.

“There’s a tremendous opportunity in the market for a North American manufacturer and solutions systems provider with a patent portfolio like ours to be able to get market penetration. And there’s about a billion dollar opportunity over the next number of years for us to own, and we think that this is the right move for us in order to capitalize on that opportunity.”

Joining Chell at the Market Open were several members of the Draganfly team, including CFO Paul Sun, COO Pat Imbasciani, and Gowling WLG Partner Denis Silva.

View the podcast for this Market Open featuring Cameron Chell here.

For more details about the CSE Media Centre, including information on upcoming Market Opens, please visit the CSE website, or follow us on social media.

RIWI Corp: Getting one’s hands on insight nobody else has requires creative thinking…and 1.5 billion responses

RIWI Corp. (CSE:RIW) runs a business for the curious, the analytical, for governments of the world, and for financial services firms looking to develop an edge. It is a business that is never the same two days in a row and thus endlessly fascinating, with the potential to drive policy, influence strategy, and bring improvements to the world at large.

In short, the company performs global trend tracking and predictive analytics that provide previously unavailable insight into how people think and behave. Relying on the Internet, it conducts surveys and can also run ad tests assessing the efficacy of corporate marketing initiatives. The company has thus far analyzed over 1.5 billion responses in putting together reports for its clients.

RIWI’s client roster includes companies in the private sector, predominantly finance, as well as groups active in humanitarian aid such as the World Bank and the Bill and Melinda Gates Foundation. Security is another area of great importance to the company.

Public Entrepreneur caught up with Founder and Chief Executive Officer Neil Seeman recently for a discussion of RIWI’s role in today’s rapidly evolving digital landscape and a look into corners of the technology world we never even knew existed.

How has technology and the market you serve changed over the last decade or so?

The market for global data collection has really exploded in the last 10 years and we’re just at the cusp of it. I feel that we’re sort of in Web 3.0 right now. I was lucky enough to have been an investor in Web 1.0 (the early days of the commercial Web) and then Web 2.0 (the social Web). Now today with Web 3.0, where RIWI sits is the world of incalculable amounts of data, and more importantly, data for actionable insights.

It’s less about Big Data these days than it is about Smart Data and that’s where we focus. And the second titanic change, which is just occurring, and where RIWI sits at a leadership position, is the importance of being an ethical data broker and only collecting data free of personal identifiers. This is becoming a game-changing issue in the world of data collection. It’s a highly competitive marketplace but the total addressable market is pretty extraordinary.

Your technology uses machine learning. Can you explain in simple terms how you collect data?

RIWI invented a global platform such that anyone with access to a Web-enabled device can stumble into a RIWI survey or ad test as they navigate the Internet and enter an abandoned domain that doesn’t exist at that moment in time – they encounter a RIWI survey or ad test on a non-trademarked domain. We invented that and expanded our intellectual property and we continually learn which constellation of domains is able to capture a perfect mirror of the Web-using audience in any region of the world. This changes in real time and we understand why and how that happens. We have a decade of historic data so we understand the changing Internet infrastructure in every country and that is a form of intelligence that can be very valuable to understanding how we can solve client needs.

How does your technology differ from that of other companies? How do you position yourself against your peers?

It’s differentiated in a number of ways. The first is global access. We have single-button technology such that you can access eight or 180 countries, or 229 territories and countries using RIWI. Otherwise, you would have to go to online panel suppliers or different market research providers in the countries.

Secondly, we reach opaque or otherwise impossible markets. We are the only continuous data provider in terms of sentiment data and ad testing data in all cities and regions across China, for example.

Thirdly, we are random in our reach. We patented and then built out a global platform and cloud-based architecture called Random Domain Intercept Technology such that the recipients who are intercepted are random and RIWI is privacy-compliant such that we are not collecting any personally identifiable data, and this fourth aspect of RIWI is highly differentiated from other digital data collection tools.

Fifth, and most importantly, we’re being recognized for broadening the voices of people who participate in surveys and ad tests. In other forms, traditional or even modern forms of sentiment collection, whether it’s social media analytics or public opinion panel-based polling or natural language algorithms using artificial intelligence, you’re getting a very, very narrow slice of public opinion, whereas with us, the majority, and in some cases the vast majority, of the people whose opinions and behavioural reactions we collect have not answered a survey or ad test of any kind in the preceding month, nor are they regular posters online.

Who are your customers and how many do you have? Can you give me an example of where your data has been particularly impactful for a client?

We currently have several dozen major enterprise clients across our business lines. They range in size. We try to build recurring revenue-based clients such that they are either quarterly subscriptions or annual subscriptions that can be renewed, sometimes on a rapid-response basis. Within each of these, some are such that they have multiple sectors or country groupings.

In terms of impactful work, we have worked for G7 agencies on strictly confidential matters, but on the unclassified side we’ve done, for example, very impactful work for the Canadian government where we’ve measured the sentiment toward women and girls and how they are treated under ISIS in 18 Middle East countries. We’ve enabled some fascinating data that have helped educate people in all regions of the world about the brutality of how women and girls are treated under ISIS.

We’ve also done a lot of work on marginalized groups, populations that don’t participate in surveys and this is not only important in the humanitarian aid sector, it’s important, for example, to the finance sector, which is trying very much to understand the future consumer of technology adoption. We’re also the largest data collector in the world for changing attitudes toward LGBTQ communities, and for undocumented citizens and people in rural communities, even in America, whose voices are often left out of important debates. We like to say we give “voice to the voiceless” in any region of the world.

It’s impactful to me when we may only solve 2% to 5% of a company’s data challenges but we are embedded with them such that they thereafter understand the universe of their other data collection needs.

The possibilities for your data seem limitless. How big can you see this getting?

Our goal is to be the Booz Allen of global data collection. We want to be everywhere in terms of our continuous data collection, in fragile and conflict states, in opaque markets, and we want to deliver data that provides actionable insights in real time. We do that with real-time dashboards that are constantly being updated such that with the touch of a button, a decision-maker can understand the truth of what’s going on, whether it’s predictions about stock market turmoil, trade wars, or gang violence.

You’re clearly growing and have been turning in quite good performance numbers of late. What is your business model? Is it the case that when revenue grows so does profitability? Are your costs mostly fixed?

One of the beautiful things the math analysts like to observe about our company from a shareholder perspective is that as our revenues grow and as our profit grows, our costs associated with sales decline or stay relatively flat. This was always embedded in the vision of the company, such that we’re not, for one, selling people, we’re selling data and dashboards and analytics, but secondly, we’re a machine-learning platform such that the technology itself is embedded, or twinned, with shareholder value creation, because the machine-learning technology continually expands in its capacity for data collection and continually decreases the costs associated with data collection. Further, our offerings are “plug-and-play” for our clients – the same issues that confront our client Bank of America Merrill Lynch also confront Asia- or Europe-based hedge funds looking for a privacy-compliant information edge.

How do you go about landing new clients?

Two ways – there’s no secret sauce here. It’s about boots on the ground and hardcore sales, using a highly disciplined sales process. I’m an accidental entrepreneur because this grew out of a small research unit I had at a college associated with the University of Toronto, and we’ve changed the mindset by going from a creative think tank environment to a heavily sales-focused enterprise with sales-focused disciplines and systems and processes.

Secondly, the uniqueness of our platform and the uniqueness of our data – especially it being privacy compliant – and the nature of our clients means that we get a lot of attention, whether it’s media attention or public presentation opportunities, or thought leadership opportunities. Our Head of Research was selected to present this Fall at TEDxToronto. Our data collection tools to generate alpha for the finance community won us a global “Battle of the Quants” award that created buzz this year.

And we also win attention from new audiences because we are in this great situation where we can generate internal data in unusual parts of the world in rapid fashion, so we offer insights that we know will be valuable and get the attention of prospective clients whose eyes light up when they see it.

This story was featured in the Public Entrepreneur magazine.

Learn more about RIWI Corp. at https://riwi.com/.

Bryan Baeumler and Lance Montgomery on Averting DIY Disasters with HeyBryan

Bryan Baeumler and Lance Montgomery, CEO of HeyBryan Media Inc. (CSE:HEY) joined James Black at the CSE Media Centre to discuss the potential of extending Bryan’s home renovation brand to a publicly traded vehicle (0:48), the mechanics of how the HeyBryan app works (1:37) and the types of renovations that are best left to professionals (2:44). Listen until the end to learn more about the company’s business model and how HeyBryan Media plans to expand the brand beyond the home services space.

Subscribe:  Apple Podcasts / Spotify / SoundCloud / Stitcher / Google Play / RSS

Oren Shuster on Serving the Medical Cannabis Market in Europe

Oren Shuster, CEO of IM Cannabis Corp., joined Barrington Miller in the podcast studio to share how the company’s foundation has been built on the experience of growing pharma-grade cannabis since 2010 (3:21), their focus on applying EU GMP standards to meet growing demand in Europe (5:13), and the important lessons learned through trial and error over the years (8:12). Listen until the end to learn more about the distinct differences between the EU/Israeli market vis-à-vis North America and the opportunity presented by the German medical cannabis market.

Subscribe:  Apple Podcasts / Spotify / SoundCloud / Stitcher / Google Play / RSS

IM Cannabis Corp Opens the Market at the CSE Media Centre

The CSE was proud to welcome IM Cannabis Corp (CSE:IMCC) to open the market at the CSE Media Centre on October 17, 2019.

IM Cannabis is a leading medical cannabis provider. Since 2010, the company has offered a full spectrum of government-licensed cannabis products, from generic to GMP-certified and pharmaceutical-grade, for both wholesale and retail clients. IM Cannabis is an industrial innovator, constantly moving forward in the rapidly developing medical cannabis market and closely collaborating with research institutions and start-up companies.

“We are enormously proud to open the market at the CSE. We’ve waited a long time for that. The team came from Israel and everybody is very excited,” remarked CEO Oren Shuster.

“IMC started in 2010 in Israel as one of the first medical cannabis companies in the world. What we have done, we have taken our know-how and expertise to Europe, and now we’re working in Europe, and we’re a pure European player. The main market that we are going to is Germany, and we will start to have substantial sales early next year. We have a very good focus for next year, and I think the fact that we are coming with the backing of clinical trials, and a lot of research done in Israel and bringing it into the EU market makes us different.”

A number of prominent members of the IM Cannabis team joined Shuster at the Market Open, including Co-Founder Rafael Gabay, COO Amir Goldstein, CFO Shai Shemesh, and more.

View the podcast for this Market Open featuring Oren Shuster here.

For more details about the CSE Media Centre, including information on upcoming Market Opens, please visit the CSE website, or follow us on social media.

Jo Vos on Empowering Cannabis Shoppers through Education

Jo Vos, Managing Director of Leafly, joined Grace Pedota in the podcast studio to share how their platform is empowering cannabis shoppers through education (2:04), the challenge of presenting plant data differently to keep pace with a rapidly maturing audience (4:02), and the importance of standardizing industry terminology (11:38). Listen until the end to learn more about Jo’s vision of how Leafly is bridging the cannabis marketing world and regulation, the ongoing opportunity to break down cannabis stigma through informed dialogue, and her personal tips for downhill cyclists!

Subscribe:  Apple Podcasts / Spotify / SoundCloud / Stitcher / Google Play / RSS

HeyBryan Media Opens the Market at the CSE Media Centre

The CSE was happy to welcome HeyBryan Media Inc. (CSE:HEY) to the CSE Media Centre for a Market Open on October 29th, 2019.

Founded in 2018, HeyBryan Media Inc. offers a home-maintenance app that allows customers to connect with vetted experts for various home-related tasks, such as handyman services, painting, plumbing, cleaning, and yard maintenance. The app is named after Canadian HGTV personality and renowned contractor, Bryan Baeumler, who was also present at the Market Open.

“Two years ago, this was just an idea. Here we are today – in Toronto, on the 72nd floor of the CSE – ringing the bell. This is a major milestone for our business, and I couldn’t be more excited,” said CEO Lance Montgomery.

“Generally, the projects we do are private. We get a lot of interest from fans and customers, and this obviously is a great opportunity to invite people to participate in our world. Having HeyBryan out there is very exciting,” said Baeumler. “You can get it anywhere you get your apps,” he added.

Several key members of the HeyBryan Media Inc. team also accompanied Montgomery and Baeumler to celebrate this momentous occasion at the CSE Media Centre.

View the podcast for this Market Open featuring Bryan Baeumler and Lance Montgomery here.

For more details about the CSE Media Centre, including information on upcoming Market Opens, please visit the CSE website, or follow us on social media.

XPhyto Therapeutics: Unique assets and a focus on Germany’s medical cannabis market set this opportunity apart

The art of successful investing is not about what is happening now, but rather figuring out what is on the horizon and set to emerge as the next big thing. Positioning oneself to make the most of that development is what gives competitors in any aspect of the business world an edge – the famed early-mover advantage.

Hugh Rogers and his team embraced this concept wholeheartedly when putting together XPhyto Therapeutics (CSE:XPHY), the company Rogers now leads as Chief Executive Officer, two years ago.

Armed with a legal background focused on corporate restructurings, plus experience in molecular biology from research work at the University of Toronto, Rogers agreed with his business partners that they wanted to participate in the burgeoning cannabis industry, yet not in the way everyone else seemed to be doing it.

Large-scale growing operations in the US and Canada did not interest the group. So, what was it that others were overlooking, something with greater potential than was to be found in the increasingly crowded North American arena?

“The vision for XPhyto was to foresee where the industry would be in two, four, and six years, and then position the company accordingly,” explains Rogers. “In the end, we decided that medical formulations and clinical validation in emerging European cannabis markets was the best place for us to be.”

That best place, to be precise, is Germany, where cannabis is legal for medical use and, according to XPhyto, not subject to the same stigma the drug suffers in North America and many other parts of the world.

“It’s a very open market in the sense that, in our experience, regulators at every level of government, and I would also say the medical community – physicians and pharmacists – are open to cannabis products,” says Rogers. “There is a history of botanical medicine in Germany where they are eager to learn but at the same time are looking for clinical validation.”

And no other entity, quite literally, is positioned in the German market the way XPhyto is to help cannabis achieve the level of formal validation that consumers expect of widely used pharmaceutical products. The company’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, possesses a German cannabis cultivation and extraction licence for scientific purposes issued by the German Federal Institute for Drugs and Medical Devices. To XPhyto’s knowledge, it is the only one in existence.

“We’re setting ourselves up to work with the government on the scientific side,” explains Rogers. “That means cultivation, extraction, remediation of oils, seed banks, tissue banks, clinical trials – all of the scientific knowledge.”

The XPhyto team has done an admirable job of building a company with top clinical talent both at the German operations and in Canada, including its recently announced cannabis research and development agreement with the Department of Biochemistry at the Technical University of Munich.

Soon to follow in Germany is a 10,000 square foot facility, half of which will house small-scale cultivation rooms, with the other half being for storage, manufacturing, and distribution. The company estimates it will be up and running with plants under cultivation in the first quarter of 2020.

Expect security levels to be high, given the structure that aptly named Bunker is renovating was once a military command centre. Bunker founder, and now XPhyto Vice President of European Corporate Development, Robert Barth will oversee the renovations. It was also Barth who brought the Technical University of Munich into the fold.

The German research bandwidth is augmented by two exclusive five-year engagements XPhyto has with the Faculty of Pharmacy at the University of Alberta. “Our primary goal in Canada is to focus on clinical validation,” says Rogers. “We have an ISO-certified clean room for our new extraction equipment for production of cannabinoid extracts and isolates. I think the first formula we’ll clinically study will be for topical dermatology followed by oncology pain management. Our expertise at the university is drug delivery and we have some unique applications for cannabis products.”

Clearly, the company’s main objective is clinical testing, and ultimately clinical trials, designed to provide the medical community with the same standard of product understanding and trust that many other prescribed treatments currently enjoy. In this way, doctors will know exactly what type of cannabis, or cannabis-derived product, to prescribe for a given condition, in what dose and for how long.

But investors and others new to the company shouldn’t conclude that the validation theme at the core of XPhyto’s model means that cash flow is something far off in the future. The supply/demand balance in Germany’s medical cannabis market features more of the latter than the former, and XPhyto is positioned to help.

“The German market is large and domestic production expected to come online in 2020 will meet only a small fraction of total demand. There is a deficit that will be made up through imports and that is an opportunity we are rapidly pursuing,” remarks Rogers.

“We are working to secure supply of ultra-premium flower in Canada,” he says in beginning to explain the import strategy. “The best premium growers are in Canada and the US. We are focused on Canada and are working with a number of great growers to source product.”

The XPhyto team believes that providing the best experience for patients must embrace testing for pesticides, heavy metals, and offering products in optimal packaging. If everything goes according to plan, product will be ready for shipping by Q1 2020.

Advancing this strategy on multiple fronts is the acquisition, announced in late August, of Vektor Pharma TF GmbH, which holds permits for cannabis importation and narcotics product manufacturing, among others. And in a possible sign of things to come, Vektor also has established itself in the research and manufacturing of thin-film strips for drug delivery, including transdermal patches and oral strips.

Said Rogers at the time of the acquisition’s announcement, “We believe that Vektor will add significant long-term value at every level of our business, from clinical trial expertise and drug manufacturing capability to their German cannabis and narcotics import licences and strong relationships with the German health authority.”

XPhyto’s strengthening German presence will be a source of many things, boots-on-the-ground intelligence being one that should enable the company to smoothly blend into the German supply scene with the long term in mind.

As an example, Rogers explains that if XPhyto has a certain volume of cannabis ready to sell it won’t necessarily put it all on the market as fast as possible. “What we want to do is build our distribution and demand through consistent supply so the physician knows when they prescribe our product that there is availability for three to six months. We would rather build our patient base slowly and steadily than flood the market – here is a whole bunch of supply and then, oops, it is not available next month. The end result when you take that approach is that physicians are less likely to prescribe your product.”

Having only made its trading debut on the Canadian Securities Exchange in August, XPhyto is a newcomer to the public markets. But asked why investors should be interested, Rogers is clear as to what sets the XPhyto opportunity apart. “It is important to understand that the cannabis industry is here to stay,” he concludes. “But at the same time, you must carefully consider where to allocate your investments. We have gone 100% into opportunities that were on the sidelines for a long time, and I think you are going to see medical applications, clinical validation, and European opportunities come to the forefront over the next two years. And that is exactly where XPhyto is positioned.”

This story was featured in the Public Entrepreneur magazine.

Learn more about Xphyto Therapeutics at https://www.xphyto.com/.

The Jamaica Stock Exchange on a New Partnership with the CSE

Marlene Street Forrest, Managing Director of the Jamaica Stock Exchange, and Ian McNaughton, Chairman of the JSE, join James Black for a special edition of #HashtagFinance to discuss the signing of a memorandum of understanding between the JSE and the CSE (0:49), how this collaboration will help create opportunities for investors on both exchanges (2:23), and which industries they believe will utilize this new ecosystem most (6:36). Listen until the end to learn more about the requirements for listing on the JSE, factors that have helped the exchange see success during their 50 years of operation, and for a very special song commemorating the JSE’s 50-year anniversary!

Subscribe:  Apple Podcasts / Spotify / SoundCloud / Stitcher / Google Play / RSS

Jason Paltrowitz and Richard Carleton on Opportunities Beyond the Border

This special episode of #HashtagFinance takes the podcast out of the studio and into the CSE Media Centre! Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group, and Richard Carleton, CEO of the Canadian Securities Exchange, join James Black to talk about Cannabis Investor Day, the inaugural event co-hosted by the CSE and OTC Markets Group (0:53), the importance of the CSE’s partnership with OTC Markets when it comes to creating opportunities for listed companies beyond the border (1:40), and why maintaining cross-border shareholder visibility is essential (6:25). Listen until the end for Jason’s explanation of the different market tiers at OTC Markets, for Richard’s advice to Canadian issuers going into the US markets, and to learn how both the CSE and OTC Markets Group help companies not only go public, but learn how to be public.

Subscribe:  Apple Podcasts / Spotify / SoundCloud / Stitcher / Google Play / RSS